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Abstract
Introduction
Crohn’s disease (CD) is a chronic inflammatory bowel disease known to carry a high risk of
disabling and many times requiring surgical interventions. This article describes a decision-
tree based approach that defines the CD patients’ risk or undergoing disabling events, surgi-
cal interventions and reoperations, based on clinical and demographic variables.
Materials and methods
This multicentric study involved 1547 CD patients retrospectively enrolled and divided into
two cohorts: a derivation one (80%) and a validation one (20%). Decision trees were built
upon applying the CHAIRT algorithm for the selection of variables.
Results
Three-level decision trees were built for the risk of disabling and reoperation, whereas the
risk of surgery was described in a two-level one. A receiver operating characteristic (ROC)
analysis was performed, and the area under the curves (AUC) Was higher than 70% for all
outcomes. The defined risk cut-off values show usefulness for the assessed outcomes: risk
levels above 75% for disabling had an odds test positivity of 4.06 [3.50–4.71], whereas risk
levels below 34% and 19% excluded surgery and reoperation with an odds test negativity of
0.15 [0.09–0.25] and 0.50 [0.24–1.01], respectively. Overall, patients with B2 or B3 pheno-
type had a higher proportion of disabling disease and surgery, while patients with later
introduction of pharmacological therapeutic (1 months after initial surgery) had a higher pro-
portion of reoperation.
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Conclusions
The decision-tree based approach used in this study, with demographic and clinical vari-
ables, has shown to be a valid and useful approach to depict such risks of disabling, surgery
and reoperation.
Introduction
Crohn’s disease (CD) is a chronic inflammatory bowel disease for which no definitive treat-
ment has been described. As so, clinicians approach the disease attempting to control the
symptoms, avoiding disease complications and improving patients’ quality of life [1]. The
most frequent CD complications are related to an uncontrolled inflammation of the bowel,
which may cause obstruction and perforation of the small intestine or of the colon, abscess, fis-
tulae and/or intestinal bleeding. The occurrence of these events may require a surgical inter-
vention, which ends up being a common strategy in CD management. In fact, previous studies
have reported that around 50% of all CD patients will eventually undergo bowel surgery within
10 years after the diagnosis, whereas 80% will eventually require a surgery throughout the
entire disease course [1,2]. Moreover, recurrence is extremely frequent, and the rate of reoper-
ations in previous studies ranged from 40% to 80% [2,3].
As for the concept of disabling, this term was introduced by Beaugerie et al. in 2006 [4] and
by Loly et al. [5] in 2008: both groups evaluated the impact of the disease using clinical and
measurable criteria. These studies reported a proportion of disabling disease between 85% and
58%, respectively. Five years after the initial study on this topic, Yang et al. [6] presented a new
report that settled the proportion of disabling at 80%. However, this last study used a slightly
different definition of disabling disease. In fact, given the rapid evolution of disease control
strategies, there is currently no consensus on the concept of disabling disease.
The definition of a strong and accurate prognosis model is a key step towards a better dis-
ease control and a higher quality of life in CD patients. In this context, this study aimed to
unveil the differential impact of several clinical and demographic variables on the CD patients’
risk of surgery, disabling and reoperation, using a decision trees-based strategy.
Materials and methods
Derivation and validation cohort
This manuscript describes a multicentric retrospective cohort study including 1547 CD
patients recruited from six Portuguese inflammatory bowel disease (IBD) specialist hospitals.
Patients were included if 1) had a definitive diagnosis of CD; 2) had at least three years of fol-
low-up; 3) had at least one consultation with a physician involved in this study during 2014 or
2015; and 4) had performed at least an X-ray computed tomography (CT) or a magnetic reso-
nance imaging (MRI) during the follow-up. A hold-out strategy was followed to enable a gen-
eralized validation of the prognostic models: the cohort was randomly split into two groups.
The first one comprised 80% of patients and constituted the derivation cohort; the held-out
remaining 20% of patients were considered to be the validation cohort.
Clinical and demographic variables
All data was retrieved from GEDII (Grupo de Estudos de Doenc¸as Inflamato´rias Intestinais,
the Portuguese IBD group) database [7] and included clinical and demographic variables, the
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dates in which the patients were submitted to bowel surgeries or started immunosuppression,
and their classification regarding steroid dependence and refractoriness. The definition of ste-
roid dependence was the inability to reduce steroids below the equivalent of 10 mg per day,
prednisolone within 3 months of starting steroids without recurrent active disease, or disease
relapse within 3 months of stopping steroids. Steroid resistance was defined as the presence of
active disease despite a prednisolone dose of up to 0.75 mg kg−1 per day over a period of 4
weeks [8]. The presence and timing of immunosuppressive medication was stratified in four
categories: 1) no pharmacological treatment; 2) pharmacological treatment both before and
after the first surgery (started within the first month after surgery); 3) pharmacological treat-
ment only after the surgery (starting more than 1 month after the first surgery); and 4) phar-
macological treatment only before the first surgery.
Outcomes analyzed
Three different outcomes were analyzed in this study:
1. disabling disease, defined as a composite endpoint characterized by the presence of at least
one of the following events: more than one abdominal surgery or two hospital admissions
in the follow-up period; steroid dependence or steroid refractoriness; need for switching
the first immunosuppression or anti-TNFα; and the appearance of new clinical events after
the index episode (stenosis, anal disease or penetrating disease)[9];
2. surgery, defined as the need for a surgical intervention (abdominal surgery only for CD);
3. reoperation, defined as the need for more than one surgical intervention (abdominal sur-
gery only for CD).
Statistical analyses
The results of the statistical analysis performed during this study are summarized into decision
trees, which are a graphical representation of a possible combination of variables based on spe-
cific conditions. It uses a divide-and-conquer strategy to solve a decision problem, which
works by dividing a complex problem into simpler problems, recursively applying the same
strategy. The different solutions of sub problems are then combined in the form of a tree to
produce a solution for the original problem. Each split in the tree (a node) is produced by spec-
ifying the percentage of the outcome present in each of the categories of one independent
variable (the one that has the highest impact at that level), while the final leaves convey an esti-
mate of the outcome for the subgroup of patients that recursively traversed the tree along that
path. Therefore, each path in the tree (from root to leaf) represents an exclusive decision rule
associated with an estimate for the outcome. Whereas most decision trees supporting clinical
decision problems are expert-based following a deductive reasoning, inductive learning the
decision tree from data, e.g. using recursive partitioning, is a valid method to generate a data-
driven decision model [10]. In order to determine the relationship between clinical/demo-
graphical factors and outcomes, decision tree classifiers were built from the derivation cohort,
applying the CHAID algorithm [11], which is based upon corrected (Bonferroni post-hoc test)
chi-squared significant testing. The following variables were analyzed for the outcomes dis-
abling and surgery: gender, smoking habits, age at diagnosis, location disease, behavior, upper
tract involvement (L4) and perianal disease. The presence and timing of medical therapeutics
were also included when considering the outcome reoperation. The decision tree parameters
were validated on the independently held-out validation cohort. The predictive quality of the
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leaves was evaluated on both cohorts estimating the proportion of the outcome for each of the
derived rules.
To assess the discriminative ability of the trees for each outcome, specific cut-off values
were chosen after analyzing the ROC curves in the derivation cohort. For disabling disease, a
rule-in approach was applied aiming at a high positive predictive value (around 80%). For sur-
gery and reoperation, a rule-out approach was applied aiming at a high negative predictive
value (also around 80%). The derived trees (defining exclusive decision rules) were evaluated
in both cohorts for the estimation of sensitivity, specificity, accuracy, predictive values, likeli-
hood ratios and post-test odds.
Variables were described through absolute (n) and relative (%) frequencies. The compari-
son between derivation and validation cohort was made applying a Chi-Square test. All
reported p-values were two-sided, for a significance level of 5%. All data were arranged, pro-
cessed and analyzed with SPSS1 v.24.0 (Statistical Package for Social Sciences).
The data collection that was used in this work has been approved by the Portuguese
National Committee of Data Protection. This study was conducted according to the principles
expressed in the Declaration of Helsinki.
Results
Population baseline characteristics and measured outcomes
The derivation cohort consisted of 1245 CD patients, the majority of them female (54%), non-
smokers (53%) and diagnosed as young adults (17 to 40 years old, 69%) (Table 1). Disease loca-
tion and behavior were classified according to the Montreal classifications [12]: 16% had
colonic disease and only 12% presented upper tract involvement. Concerning behavior, 46%
had a non stricturing/non penetrating phenotype, whereas 26% had perianal disease. Disabling
disease occurred in 68% of patients, 47% underwent bowel surgery, and 38% (among the lat-
ter) needed reoperation.
Disabling disease
Disabling disease occurred in 68% of the derivation cohort patients. The induced decision
tree, computed from all independent variables with the exception of the presence and timing
of pharmacological therapy (as this variable is itself involved in the disabling definition),
resulted in a three-level model (Fig 1). The first level was defined by the behavior phenotype, a
two-way split that separated the risk for disabling of B1 (54%) apart from that of B2 and B3
phenotypes (80%). The second level consisted in the presence of perianal disease. Location and
gender defined the third level for patients that had the B1 phenotype and the absence or pres-
ence of perianal disease, respectively. The set of rules defined by this tree can be summarized
by the different risk levels (32% to 90%) reported in Table 2. Overall, patients with phenotypes
B2 or B3 have a higher risk of disabling disease, while for phenotype B1, gender plays an
important role, with female patients having a higher risk than males.
Surgery
The outcome surgery affected 47% of the derivation cohort patients. The induced decision
tree, computed using the same variables as those used for the disabling decision tree, resulted
in a two-level model (Fig 2). As for the disabling, the first level was defined by disease behavior,
although in this case a three-way split separated the surgery risk of all phenotypes: 16% for B1,
68% for B2, and 75% for B3. The second level of the model included information on upper
track involvement (L4) (for patients with the B2 phenotype) and gender (for patients with the
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B3 phenotype). The set of rules hereby defined represent different risk levels (17% to 81%),
which are depicted in Table 2. Globally, patients with a B3 phenotype have a higher risk of sur-
gery than those with a B1 behavior, and this risk is further aggravated in male B3 patients.
Reoperation
The rate of reoperation was defined among those patients that underwent bowel surgery: 38%
required additional surgical interventions. The induced decision tree, computed using all vari-
ables described before and including the timing and presence of pharmacological therapeutics,
resulted in a three-level model of variables (Fig 3). The first level was defined by the presence
and timing of the anti-TNF introduction, separating those that started anti-TNF more than
one month after surgery (53% of reoperation risk) from all the others (29% of reoperation
risk). The second level included behavior for the former (stratified in B1 vs. B2/B3) and pres-
ence and timing of AZA introduction for the later (discriminating between patients that have
either never been medicated or been medicated only before surgery from the remaining). The
third level encompassed the disease location, separating L1 from L2 and L3. The defined set of
Table 1. Baseline characteristics and comparison between the derivation and the validation cohorts.
Derivation
(n = 1245)
Validation
(n = 302)
p-value
Gender 0.409
Male 577 (46%) 132 (44%)
Age at diagnosis .682
A1 - < = 16 years 138 (11%) 37 (12%)
A2- 17–40 years 865 (69%) 212 (70%)
A3- >40 years 242 (19%) 53 (18%)
Location 0.246
L1—Ileon 542 (44%) 120 (40%)
L2 –Colonic 200 (16%) 44 (15%)
L3—IleoColonic 503 (40%) 138 (46%)
Upper tract involvement (L4) 152 (12%) 27 (9%) 0.111
Behaviour 0.431
B1—Non-Stricturing/non-penetrating 572 (46%) 146 (48%)
B2—Stricturing 308 (25%) 64 (21%)
B3—Penetrating 365 (29%) 92 (30%)
Perianal disease 327 (26%) 80 (26%) 0.937
AZA 0.403
No AZA 794 (64%) 199 (66%)
AZA before and after surgery (<1 month) 79 (6%) 16 (5%)
Aza only after surgery (>1 month) 270 (22%) 70 (23%)
Aza before surgery 102 (8%) 17 (6%)
Anti TNF 0.835
No anti TNF 943 (76%) 234 (77%)
anti TNF before and after surgery (<1 month) 44 (4%) 9 (3%)
anti TNF only after surgery (>1 month) 224 (18%) 53 (18%)
anti TNF before surgery 34 (3%) 6 (2%)
Disabling disease 849 (68%) 206 (68%) 0.995
Surgery 579 (47%) 135 (45%) 0.573
Reoperation 220 (38%) 45 (33%) 0.313
doi:10.1371/journal.pone.0172165.t001
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rules resulted in different risk levels (13% to 58%) that are listed in Table 2. Overall, patients
with a later introduction of pharmacological intervention (1 month after initial surgery) had a
worse outcome, i.e, they have a higher probability of undergoing more than one surgery dur-
ing the disease course.
Model validation
The validation cohort consisted of 302 patients and was similar to the derivation cohort con-
cerning the frequency of the analyzed variables and outcomes (Table 1). The risk of each out-
come following the decision rules extracted from the trees in the derivation and validation
cohorts (S1 Fig). The proportion of the outcomes is similar in both cohorts, and their confi-
dence intervals are overlapping, therefore attesting the robustness of the decision rules.
Fig 1. Decision tree for disabling disease.
doi:10.1371/journal.pone.0172165.g001
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Receiver operating characteristic (ROC) analysis were performed independently for the
derivation and validation cohorts and the respective AUC values were similar in and had over-
lapping 95% CI for disabling and surgery, but not for reoperation (S2 Fig). Moreover, the
AUCs were rather heterogeneous for the different outcomes: the derivation cohort presented
an AUC of 72% for disabling, 80% for surgery and 69% for reoperation.
The derivation cohort ROC curves were used to establish cut-offs able to assess the likeli-
hood of the occurrence of each outcome. Positive results were defined for risk levels above
75% concerning disabling disease, above 34% concerning surgery, and above 19% concerning
reoperation. These cut-offs enabled the computation of a simplified set of rules that are listed
in Table 2. The performance parameters of the chosen cut-offs considering each outcome are
depicted in Table 3 for the derivation and the validation cohorts. Most of the 95% CI over-
lapped between both cohorts, once again validating the initial model. Overall, the application
of the cut-offs to the validation cohort resulted in 81% [74%-86%] PPV for disabling disease,
87% [80%-92%] NPV for surgery, and 67% [57%-75%] for reoperation.
Discussion
Given the impact and frequency of recurrences among CD patients, the development of prog-
nostic models is a cornerstone to guide physicians in their therapeutic choices and to improve
patients’ well-being. The most important characteristics of these models are their user-friendli-
ness and readability, allowing a fast and effortless readout during patient encounters or upon
the need to decide on a therapeutic approach.
Table 2. Decision rules and proportion and confidence intervals of outcomes observed.
Disabling Disease
Proportion of outcome For cut-off of 75%
B1 & No Perianal & L1 31.5% [24.4%-38.6%] 46.8% [42.0%-51.6%]
B1 & No Perianal & L2/L3 56.7% [50.6%-62.8%]
B1 & Perianal & Male 66.7% [55.8%-77.6%] 66.7% [55.8%-77.6%]
B1 & Perianal & Female 82.7% [74.5%-90.9%] 82.7% [74.5%-90.9%]
B2/B3 & No Perianal 76.4% [72.7%-80.1%] 79.9% [76.8%-82.8%]
B2/B3 & Perianal 90.2% [87.8%-94.6%]
Surgery
Proportion of outcome For cut-off of >34%
B1 16.6% [13.5%-19.7%] 16.6% [13.5%-19.7%]
B2 & No L4 72.0% [66.4%-77.6%] 68.2% [62.3%-73.1%]
B2 & L4 51.7% [38.44%-64.6%]
B3 & Male 81.2% [75.3%-87.1%] 75.1% [70.4%-79.2%]
B3 & Female 69.7% [63.3%-76.2%]
Reoperation
Proportion of outcome For cut-off of > 19%
TNF after surgery (> 1 month) & B2/B3 57.9% [50.9%-64.9%] 52.7% [46.2%-59.1%]
TNF after surgery (> 1 month) & B1 23.5% [9.3%-37.8%]
TNF (without, before or before and after surgery) & AZA (without or only before surgery) & L1 13.3% [6.6-%-20.0%] 13.3% [6.6%-20.0%]
TNF (without, before or before and after surgery) & AZA (without or only before surgery) & L2/L3 28.9% [18.7%-39.1%] 28.9% [18.7%-39.1%]
TNF (without, before and before or after surgery) & (AZA after or before and after surgery) 37.0% [30.3%-44.3%] 37.0% [18.7%-39.1%]
Logical operators: & (AND); White—< = 10%; green– 11–19%; Yellow– 20%-49%; Orange– 50%-74% and red> = 75%
doi:10.1371/journal.pone.0172165.t002
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This cohort presented a disabling rate of 68%, a similar value to that depicted in previous
studies of different Portuguese cohorts [9,13]. However, other authors have reported higher
disabling rates [4–6]. This difference is likely due to the fact that the disabling definition used
in this study is stricter than that used in previous ones, namely by excluding the need of immu-
nosuppression or anti-TNF as criteria. In our opinion, the introduction of pharmacological
therapy not qualify as disabling, given the top-down and accelerated step-up strategies cur-
rently followed to approach CD.
Surgery, on its turn, affected 47% of the patients in the derivation cohort. This value is
lower than that presented by Bernal et al. [2], which could be related to the fact that the cohort
analyzed in that study was composed of older patients (data collected since 1955). The rapid
evolution of CD therapeutics and the current strategies used to approach the disease, together
with the fact that our cohort included patients that have been more recently diagnosed,
explains our lower surgery rate. Moreover, a recent meta-analysis has reported a 47% risk of
surgery within 10 years after diagnosis [14], thereby supporting the results described here.
Reoperation, on the other hand, affected 38% of the patients who underwent a first surgery, a
rate similar to that presented in a recent meta-analysis that settled the 10-years risk of reopera-
tion at 33% [15].
Fig 2. Decision tree for surgery.
doi:10.1371/journal.pone.0172165.g002
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The results from this study are depicted in three decision trees that represent the risk for
each of the outcomes described above taking into specific combinations of clinical and demo-
graphic variables. These decision trees were validated in an independent cohort by; a) com-
paring the proportion of the outcome in each derived rule; and b) comparing the diagnostic
Fig 3. Decision tree for reoperation.
doi:10.1371/journal.pone.0172165.g003
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performance parameters using specific risk cut-off levels. The proportion of each outcome
following the decision rules in the different cohorts was similar. Moreover, the comparison
of the diagnostic performance parameters revealed that the decision trees had a good prog-
nostic ability of concerning disabling disease and surgery: the validation cohort had a positive
post-test odds for disabling disease of 4.24 [3.09–5.81], and a negative post-test odds for sur-
gery of 0.15 [0.09–0.23]. Reoperation, on the other hand, appeared to a harder outcome to
predict, presenting a less favorable performance among the validation cohort patients. This
might indicate that other factors—besides those that have been considered—need to be
included in the model. Nevertheless, the negative post-test odds of the validation cohort were
0.5 [0.24–1.01], and therefore this model might still be useful to detect patients with a lower
risk of reoperation.
The variables used in the decision tree were chosen by applying the CHAID algorithm,
which is similar to the chi-square with Bonferroni correction post hoc test. The final selection
of variables was the same as that used in previous studies that employed different selection
methods, therefore attesting the robustness of the computed decision trees [2,4–6,16–18]. The
decision tree analysis has a some advantages over others that are more widely used (e.g. logistic
regression). An undeniable strength of this method is its graphical representation, which
allows a quick and intuitive reading. On the other hand, decision trees are rather flexible in the
way that they do not assume any data distribution. Another advantage is the attribute selec-
tion, which restricts the variables in the model to those that are non-redundant. The interpret-
ability of the trees is also one their strong points—complex decisions can be approximated by
simple or local decisions. Finally, decision trees allow an easy comparison of patients’ sub-
groups, as decision rules can be created directly from the tree. Overall, patients with B2 or B3
phenotype had a higher proportion of disabling disease and surgery, while patients with later
introduction of pharmacological interventions (one month after initial surgery) had a higher
proportion of reoperation. Although analyzed in a retrospective-fashion and using retrospec-
tively-defined outcomes, this study presents an analysis of a large multicentric cohort formally
validated by the application of the derived results in a validation cohort.
In conclusion, we have shown that variables such as disease behavior, upper gastrointestinal
involvement, gender, perianal disease, location and medical therapeutics affect the risk of dis-
abling disease, surgery and reoperation in CD patients. Moreover, these variables impact the
aforementioned outcomes at different levels, having different weights in sub-groups of patients
with different variables’ combinations. Our results are represented in three graphical and user-
Table 3. Performance of risk matrix in derivation and validation cohort for disabling disease and reoperation (% [CI 95%]).
Disabling >75% Surgery >34% Reoperation >19%
Derivation Validation Derivation Validation Derivation Validation
Sens 71 [68–74] 67 [61–74] 84 [80–86] 86 [78–91] 94 [89–97] 87 [73–94]
Spec 62 [57–74] 65 [55–75] 72 [68–75] 76 [69–82] 24 [19–28] 13 [7–23]
PPV 80 [77–83] 81 [74–86] 72 [68–75] 74 [66–81] 43 [39–48] 33 [8–21]
NPV 50 [45–55] 48 [40–58] 83 [80–86] 87 [80–92] 87 [78–92] 67 [57–75]
LR+ 1.89 [1.66–2.16] 1.97 [1.47–2.65] 2.94 [2.60–3.34] 3.59 [2.71–4.74] 1.23 [1.15–1.32] 1.00 [0.67–1.15]
LR- 0.46 [0.41–0.51] 0.49 [0.40–0.60] 0.23 [0.19–0.28] 0.19 [0.12–0.28] 0.25 [0.14–0.43] 1.00 [0.41–2.43]
Odds post test+ 4.06 [3.50–4.71] 4.24 [3.09–5.81] 2.56 [2.25–2.92] 2.90 [2.18–3.85] 0.75 [0.66–0.86] 0.5 [0.37–0.67]
Odds post test- 0.99 [0.90–1.08] 1.05 [0.87–1.26] 0.20 [0.16–0.24] 0.15 [0.09–0.23] 0.15 [0.09–0.25] 0.5 [0.24–1.01]
Sens: Sensibility; Spec: Specifity; PPV: Positive Predictive value; NPV: Negative Predictive value; LR+: Positive Likelihood ratio: LR-: Negative Likelihood
ratio
doi:10.1371/journal.pone.0172165.t003
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friendly bedside tools that can be used by the physicians to assess the risk of disabling, surgery
and reoperation in CD patients, therefore supporting the decision making process regarding
therapeutic strategies. A disabling risk above 75% allows the prediction of disabling events
with a PPV of 81% and an odds post-test positivity of 4.24, whereas a surgery risk inferior to
34% allows the exclusion of future surgeries with a NPV of 87% and an odds post-test negativ-
ity of 0.15. The reoperation was the hardest outcome to predict, although a risk below 19%
could be useful for excluding future events (NPV: 87 and odds post-test negativity: 0.5).
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